Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05872126
Other study ID # AssiutMedicCTS
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 1, 2023
Est. completion date April 30, 2025

Study information

Verified date May 2023
Source Assiut University
Contact Kareem A Hosny, M.SC
Phone 01000401994
Email kareemdna94@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Malignant Pleural Effusion (MPE) is considered to be a common presentation at malignant tumors representing 15% of all cancer cases. It carries a burden on our patients with dyspnea being the most common symptom in most of cases. Management of symptomatic malignant pleural effusion remains to be a point of debate. Data available from literature shows conflicting results lacking high quality evidence which necsscitates further research work. Options differs to include chemical pleurodesis using medical or surgical talc poudrage or slurry. Surgical intervention with abrasion pleurodesis or pleurectomy using VATS approach has been used in many studies. Using indwelling pleural catheters (IPCs) has also proved comparable efficacy at many clinical trials. In this study we want to help answering this question so that we can add to the current knowledge aiming to offer the best care for those patients


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date April 30, 2025
Est. primary completion date March 31, 2025
Accepts healthy volunteers No
Gender All
Age group 5 Years to 90 Years
Eligibility Inclusion Criteria: - 1-patients with symptomatic malignant pleural effusion. 2- symptomatic patients with shortness of breath. 3-Lung can be fully expanded. Exclusion Criteria: 1. Patients with non symptomatic malignant pleural effusion 2. Pleural symphysis with no potentiality for re-expansion 3. Patients managed surgically through open thoracotomy. 4. Pleural effusion due to causes other than malignancy 5. Loculated malignant effusion judged by chest ultrasound 6. Trapped lung due to malignant pleural effusion assessed by multislice CT chest., 7. .Refusal to share the research project and not to sign the consent.

Study Design


Intervention

Procedure:
VATS-Surgical pleurodesis
VATS drainage and surgical abrasion.
Tube Drainage
Tube drainage for malignant pleural effusion

Locations

Country Name City State
Egypt Assiut university heart hospital Assiut

Sponsors (1)

Lead Sponsor Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total hospital stay duration of hospital stay in days 3 months postoperative
Primary duration of airleak duration in days 3 months postoperative
Secondary Status of performance patient reported outcome through a pre-prepared questionnaire 3 months
Secondary mortality Rate of mortality '3 months
Secondary Failure of management time to re-collection 3 months
See also
  Status Clinical Trial Phase
Completed NCT00052338 - Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer Phase 1
Recruiting NCT06421610 - OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion. Phase 1
Recruiting NCT04793607 - Interventions for Malignant Pleural Effusions Impact on Fatigue
Recruiting NCT03987087 - A Randomized Study of Primary Tumor Radiotherapy for Patients With MPE Stage IV NSCLC Phase 2
Recruiting NCT02942043 - Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer Phase 2
Completed NCT01997190 - Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion Phase 1
Completed NCT00564733 - FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer Phase 2
Not yet recruiting NCT04131231 - Safety and Effectiveness of MPCD Therapy on the Treatment of Malignant Pleural Effusion N/A
Completed NCT02674243 - Efficacy of Iodopovidone Versus Talc in Palliative Malignant Pleural Effusion Phase 3
Terminated NCT01004510 - Zometa Adjuvant Treatment of Malignant Pleural Effusion Due To Non-Small Cell Lung Cancer Phase 2
Completed NCT00528645 - AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer Phase 2
Recruiting NCT00313066 - Comparison the Level of CTGF Protein and Related Cytokine in Pleural Effusion Phase 4
Terminated NCT04236037 - Ultrasound-guided Biopsy of the Pleura as a Supplement to Extraction of Fluid in Patients With One-sided Fluid in the Pleura N/A
Completed NCT05372055 - Malignant Pleural Effusions: Evaluating the psYchosocial Impact of Indwelling Pleural Catheters on Patients
Not yet recruiting NCT04914598 - A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions Phase 3
Recruiting NCT04322136 - AMPLE-3: IPC Plus Talc vs VATS in Management of Malignant Pleural Effusion N/A
Recruiting NCT03973957 - Talc Outpatient Pleurodesis With Indwelling Catheter N/A
Recruiting NCT05923515 - A Phase I Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion Phase 1
Completed NCT02649894 - Safety and Effectiveness of a New Pleural Catheter for Symptomatic, Recurrent, MPEs Versus Approved Pleural Catheter N/A
Recruiting NCT03403855 - Rocket® Pleural Catheters: QOL, Feasibility and Satisfaction in Recurrent MPE Patients N/A